Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Operating Expenses: 2023-2025

Historic Operating Expenses for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to $10.3 million.

  • Mereo BioPharma Group's Operating Expenses rose 10.05% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year increase of 17.71%. This contributed to the annual value of $47.4 million for FY2024, which is 32.15% up from last year.
  • Mereo BioPharma Group's Operating Expenses amounted to $10.3 million in Q3 2025, which was down 5.08% from $10.9 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Operating Expenses peaked at $15.3 million during Q4 2024, and registered a low of $6.4 million during Q2 2023.
  • Over the past 3 years, Mereo BioPharma Group's median Operating Expenses value was $10.3 million (recorded in 2025), while the average stood at $10.5 million.
  • Within the past 5 years, the most significant YoY rise in Mereo BioPharma Group's Operating Expenses was 100.81% (2024), while the steepest drop was 15.79% (2024).
  • Quarterly analysis of 3 years shows Mereo BioPharma Group's Operating Expenses stood at $8.4 million in 2023, then soared by 81.82% to $15.3 million in 2024, then rose by 10.05% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $10.9 million for Q2 2025, and $11.2 million during Q1 2025.